Amber Siegfried

Bachelor of Medicine and Bachelor of Science,  Massachusetts General Hospital 

Location: Africa

Consulting Services

Case Consulting Scientific Writing Pharma-CRO-Device

Areas Of Interest

Experimentation, Animal Adrenal Medullas Calophyllum Ugurol Enterovirus 68, Human External Defibrillator Deficiency, Acid Alpha-Glucosidase Visual Cortex Personal Expenditures Medroxyprogesterone 17-Acetate Safety Based Medical Device Withdrawals Splint, Dynamic Orf virus Venoms, Fish Palm, Rattan T-Cell Receptors delta-Chain Brucelloses, Bovine Cells, GABA Gangrenes, Pulp Tomographies, Radionuclide Computer-Assisted Opal Codon CP 45899 Corneal Granular Dystrophies Large Granular Lymphocytoses Nucleopolyhedrovirus Facility, Health Disease Managements Indolylacetic Acids Biogenic Monoamines Unified Parkinson's Disease Rating Scale Progeria-Like Syndrome Monkey, Japanese Oxosteroids Length of Stay Skin Response, Galvanic Regulatory Subunit RIIalpha, Cyclic-AMP-Dependent Protein Kinase Cancer, Sigmoid Colon Sympathectomies PHGPx Enzyme

Professional Narrative

Dr. Amber Siegfried was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Siegfried has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.


Employment

Director Medicine, Mayo Clinic 2019
Medical Writer, Harvard Med 2005

Education

Director Medicine, Yale School of Medicine 1998
Doctor of osteopathic medicine, Perelman School of Medicine 1998

Referees


Publications

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175-196. doi: 10.1038/s41573-018-0006-z. PMID: 30622344; PMCID: PMC6410566.

Yin X, Mead BE, Safaee H, Langer R, Karp JM, Levy O. Engineering Stem Cell Organoids. Cell Stem Cell. 2016 Jan 7;18(1):25-38. doi: 10.1016/j.stem.2015.12.005. PMID: 26748754; PMCID: PMC4728053.

Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Hacohen N, Regev A, Feng G, Sharp PA, Zhang F. CRISPR- Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014 Oct 9;159(2):440-55. doi: 10.1016/j.cell.2014.09.014. Epub 2014 Sep 25. PMID: 25263330; PMCID: PMC4265475.

Tang Z, Kong N, Zhang X, Liu Y, Hu P, Mou S, Liljeström P, Shi J, Tan W, Kim JS, Cao Y, Langer R, Leong KW, Farokhzad OC, Tao W. A materials-science perspective on tackling COVID-19. Nat Rev Mater. 2020;5(11):847-860. doi: 10.1038/s41578-020-00247-y. Epub 2020 Oct 14. PMID: 33078077; PMCID: PMC7556605.


Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :


Languages

Language Proficiency :

Translation Services :